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Autism is a complex neurodevelopmental disorder characterized by impairment of social interaction, language, communication,
and stereotyped, repetitive behavior. Genetic predisposition to autism has been demonstrated in families and twin studies.
About 5–10% of autism cases are associated with chromosomal abnormalities or monogenic disorders. The identiﬁcation of
genes involved in the origin of autism is expected to increase our understanding of the pathogenesis. We report on the clinical,
cytogenetic, and molecular ﬁndings in a boy with autism carrying a de novo translocation t(7;16)(p22.1;p11.2). The chromosome
16 breakpoint disrupts the paralogous SLC6A8 gene also called SLC6A10 or CT2. Predicted translation of exons and RT-PCR
analysis reveal speciﬁc expression of the creatine transporter paralogous in testis and brain. Several studies reported on the
role of X-linked creatine transporter mutations in individuals with mental retardation, with or without autism. The existence
of disruption in SLC6A8 paralogous gene associated with idiopathic autism suggests that this gene may be involved in the autistic
phenotype in our patient.
Copyright © 2008 Nadia Bayou et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Autism is deﬁned as a pervasive neurodevelopmental dis-
order with onset before 36 months of age, resulting in
impairment in social interaction, communication, and in a
manifestationofrepetitive stereotypicbehavior.Itsincidence
is estimated at about 1/1000 to 1/2000 with a biased male-to-
female ratio of three or four to one (3-4:1) [1]. The exact
aetiology of autism remains unknown, although it is likely to
result from a complex combination of genetic, neurological,
immunological, and environmental factors [2]. Genetic
factors for autism have been well established in family and
twin studies. The concordance rate in monozygotic twins is
estimated to be 90%. This rate is between 0% and 24% in
dizygotic twins [3].
About 3–6% of autism cases are associated with chromo-
somal abnormalities [4]. Positional cloning of translocation
or inversion breakpoints has been a successful way of
identifying candidate genes for many genetic disorders. The
underlying assumption is that a gene disrupted by the
breakpoint is causative of the phenotype. Therefore, as an
alternative way to identify candidate genes for autism, we
analyzed the breakpoint regions of de novo translocation
t(7;16)(p22.1; p11.2) in a patient with autism. To the best
of our knowledge, there are few published reports of patients
with autism carrying chromosomal translocation located on
16p11.2 [5].
2.MaterialsandMethods
2.1. CaseReport
Our patient is the younger of two children born at term of
non consanguineous healthy parents. Patient’s psychomotor2 Comparative and Functional Genomics
delays were noticed in the ﬁrst months of life. He was
unable to maintain eye contact and presented many motor
stereotypes and ritualistic behaviors such as cutting papers
into small pieces and aligning objects. Pregnancy was
uneventful. Delivery was by caesarean section secondary to
a narrow basin. Birth weight was 3350g, and no recognized
malformations were noted. The patient could not sit alone
before 12 months neither could he walk alone before 26
months. He never achieved continence and still needed help
in eating, and complete assistance in dressing and self care.
The patient had severe language impairment being
only able to pronounce monosyllabic words, without any
relational intent. A clinical evaluation performed at the age
of 4 years revealed a weight of 13kg (−2SD), a height of
102cm (normal), and an occipitofrontal head circumference
of 48cm (−2, 3SD). No evident dysmorphic features were
noted.
The clinical diagnosis of autism was made according to
the Diagnostic and Statistical Manual of Mental Disorders—
Revision 4 (DSM-IV) and the Autism Diagnostic Interview,
French version 6 1993 (ADI-R) criteria at the age of 4 years
and 11 months. The Childhood Autism Rating Scale, French
version (CARS-T) scale indicated a score of 45 documenting
a high level of autistic behavior. The IQ test was crucial
in conﬁrming the mental retardation diagnosis. It was not
carried out as the parents declined this. The MRI of the
brain revealed a cerebellar megacisterna in the posterior
fossa. The MRS showed a normal spectral pattern as well for
the creatine as for the remaining metabolites. Creatine and
creatinine concentrations in body ﬂuids were not evaluated
as the parents refused this. Southern blot analysis revealed
the absence of FRAXA mutation. The healthy sister was not
available for analysis.
2.2. Cytogeneticand FISHStudies
Chromosome analysis was performed on the proband’s and
parent’s blood, using standard high-resolution techniques.
FISH was performed on the proband’s metaphase with BACs
that were selected according to the UCSC Genome Browser,
and provided by BACPAC Resource Centre (BPRC) and Pr.
Mariano Rocchi (University of Bari, Italy). BAC clones were
biotinylated with biotin-11-dUTP (Sigma, Mo, USA) by nick
translation using the BioNick labeling system (Invitrogen
Life Technologies).
2.3. Bioinformatic Research
Bioinformatic search was carried out using the UCSC
Genome Browser to identify potential autism candidate
genes. The Genomatix Software was used for the promoter
and the gene structure predictions.
2.4. ExpressionStudies
Total RNA was isolated and puriﬁed using the RNAgents
Total RNA Isolation System (Promega) from peripheral
white blood cells and other human tissues (testis, adult and
Table 1: Exon/intron organization of the human SLC6A8 paralo-
gous gene.
Exon no. Exon size Sequence at exon/intron boundaries
(bp) 5  donor 3  acceptor
1 266 NA CGGAGgtgag
2 132 cccagGTGTG CAAAGgtgag
3 250 cccagGCCTG TGGGAgtgag
4 133 cctagGAACA GAAAGgtacc
5 135 cccagATCGT CTCAGgtgag
6 103 tctagGTATG TACAAgtaag
7 125 cccagCAGCC GTCAGgtagg
8 113 cacagGGCGG GCTTGgtctc
9 138 cacagTTTGT CTGATgtgag
10 103 cccagGGTGG GTATGgtagg
11 101 cacagGAGCT GCATGgtaag
12 171 tgtagGGCAT CTGAGgtaag
13 1984 tgcagTGCTG NA
∗Intron nucleotides are in lowercase letters, exon nucleotides are in capital
letters.
∗∗ NA: not applicable.
foetal brain, ﬁbroblasts, and kidney). 1μg of total RNA was
converted to cDNA was used in 25μL reactions with AMV
PCR Master Mix (Promega).
A 4 nucleotides insertion in the 1st exon of the SLC6A8
paralogous gene let us to design speciﬁc primers with Web
Primer DNA program (insertion not found in the SLC6A8
gene).
RT-PCR assays speciﬁc for the chromosome 16 paralo-
gous SLC6A8 transcript and direct sequencing were done
using these speciﬁc primers (5 -TACCGCTTCTTCTCG-
CGGCTCTTG-3 ,a n d5  -ATCGCGCGCGGCGGCACG-
GC-3 ).
3. Results
The G-band pattern established a 46, XY, t(7;16)(p22; p11)
karyotype (Figure 1(a)). The mapping of the chromosome
7p22.1 breakpoint demonstrates that no gene was disrupted
in the interval (data not shown).
As shown in Figure 1(c), the RP11-264M14 BAC hy-
bridized both to derivative 7 and derivative 16 and to the
normal chromosome 16 but not to the normal chromosome
7( Figure 1(b)), indicating that this clone spans the translo-
cation breakpoint on chromosome 16p11.2 (Figure 1(c)).
The clone RP11-264M14, on 16p11.2, was found to be
devoid of known genes but it included an entire mRNA
predictedtobeparalogoustothehumancreatinetransporter
gene (SLC6A8) located on Xq28. The chromosome 16
paralogous gene is spanning 486952bp of chromosome 16
(33,205,876-33,692,827).
Our bioinformatic research ruled out with the Geno-
matix Software predicted for the paralogous gene a structure
of13exonswithintron-exonjunctionsconformingtosplice-
site consensus sequences (Table 1).
T h ep r e d i c t e dm R N Af o rt h i sp a r a l o g o u sg e n e( X R
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Figure 1: Physical mapping of the breakpoint on chromosome 16. (a) The patient derivative chromosomes 7 and 16 are shown. By
comparison to the both respective ideogrammed chromosomes, the breakpoints were located in 7p22 and 16p11.2. (b) FISH analysis with
the BAC RP11-264M14B22 (green) located in 16p11.2 and a centromeric probe of chromosome 7 (red) shows that this BAC is spanning the
breakpointonchromosome7.(c)Physicalmapofgenomicregion16p11.2derivedfromtheMay2006versionoftheUCSCGenomeBrowser
(http://www.genome.ucsc.edu/). The genomic clones covering the region ﬂanking the translocation breakpoint are indicated by simple black
lines.Thearrowindicates thepositionofthetranslocationbreakpoint withregardtothegenomic clones.Theredlinerepresentsthelocation
of the predicted gene.
and an ORF of 441 amino acids. A predicted 1414bp
promoterislocatedbetweennucleotides33,684,872,and33,
686, 285 of the genomic DNA sequence contig NT 010393.
The cDNA sequence contained 1846bp of 5 -UTR and
1230bp of 3 -UTR.
NCBI BLAST homology search analysis revealed that the
nucleotide sequence of this paralogous gene is 97.1% similar
to the SLC6A8 gene.
RT-PCR assays speciﬁc for the chromosome 16 paralo-
gous SLC6A8 transcript and direct sequencing by primers
identiﬁed a speciﬁc expression in foetal and adult brain and
in testis. The results indicated no expression of this gene
control blood cells and ﬁbroblasts (Figure 2). Although we
did not identify the actual sequence of the breakpoint, we
mapped it between 33.28Mb and 33.31Mb corresponding
to the promoter region.
4. Discussion
Substantial evidence suggests that chromosomal abnormal-
ities contribute to autism risk but the exact prevalence is
SLC6A8 paralogous gene
LT B f B B lF K
Figure 2: Expression pattern of the SLC6A8 paralogous gene. (RT-
PCR was done on RNA extracted from various human tissues. L:
l a d d e r ;T :t e s t i s ;B :b r a i n ;f B :f o e t a lb r a i n ;B l :b l o o d ;F :ﬁ b r o b l a s t ;K :
kidney).
unclear because literature surveys span diﬀerent diagnostic
and cytogenetic approaches and sample sizes. Recent studies
show rates of detected chromosomal abnormalities in 5%–
10% of aﬀected individuals [6].
A genome-wide analysis of structural variations ruled by
Marshalletal.[7]identiﬁedanautismsusceptibilitylocuson4 Comparative and Functional Genomics
16p11.2 involving deletions and duplications. They reported
that this copy number variation (CNV) region was found at
near to 1% in the studied autistic cohort and not in controls.
A region on chromosome 16p11.2 (from genomic coor-
dinates 29.5Mb to 30.1Mb) was found deleted de novo
in autistic patients [8]. Kumar et al. [9] suggested that
the 16p11.2 microdeletion is one of the most common
recurrent genomic disorders associated with autism. The
question to rise is whether these deletions removed the
coding regions of some genes. This region is nearby of
the translocation breakpoint characterized in our autistic
patient (from genomic coordinates 33.28Mb to 33.31Mb)
corresponding to the promoter region of the human creatine
transporter gene (SLC6A8) paralogous.
This gene has been localized to 16p11.2 by two studies
[10, 11]. It is also known as SLC6A10 or CT2 [12]. The
mRNAsequenceBC012355reportedbyStrausbergetal.[13]
is 2168bp with a coding sequence of 1908bp and 636 amino
acids predicted.
Eichler et al. [11]a n dH¨ oglund et al. [14] have identiﬁed
the SLC6A10 gene as a pseudogene with an early stop codon.
However, this gene has been considered to be a functional
gene both in UniGene at NCBI as well as in a review article
by Chen et al. [15].
ThisgenewasfoundspeciﬁcallyexpressedintestisbyIyer
et al. [10]. They suggested that this gene function is critical
for creatine transport into the cell to ensure normal sperm
mobility.
Our data extend this ﬁnding; this is the ﬁrst time
this phenotype has been reported for the chromosome 16
SLC6A8paralogous,andtheﬁrsttimeexpressionofthisgene
has been reported in brain as well as testis.
The SLC6A8 genes are members of a superfamily of pro-
teins that includes the family of Na+ and Cl− dependent
transporters responsible for the uptake of certain neuro-
transmitters (e.g., dopamine, GABA, serotonin, and nora-
drenaline) and amino acids (e.g., glycine, proline, and
taurine) [16].
Szatmari et al. [6] reported that some members of the
solutecarrierfamilyfallinpositivelinkageregionsforautism
or close to linkage peaks. Even if they have not glutamatergic
synaptic function, some members aﬀect brain development
and constitute excellent candidate genes for autism.
There is a high prevalence of SLC6A8 mutations in X-
linked mental retardation. Common features of X-linked
mental retardation are neurological disturbances including
seizures, behavioral problems, speech delay, and inability to
engage in structured play [17]. Our patient was diagnosed
with a high level of autistic behavior and severe delay both in
speechandinexpressivelanguagefunction.Wehypothesized
that this phenotype is the result of the creatine transporter
paralogous disruption by the translocation breakpoint on
16p11.2.
The disruption of this gene may cause a decreased dosage
responsible for speciﬁc tissue and developmental eﬀects
leading to autistic traits.
This data is in agreement with the deletions on 16p11.2
reported by Marshall et al. and carried only by autistic
patients [7]. The authors suggested that the loss of some
genes in the interval is critical for the development of speech,
language, and communication.
As gene expression is the basis of many crucial functions
in the cell, the hypothesis is that perturbation in the network
of genes by the translocation or the CNVs in this speciﬁc
region cause the related pathology by dosage diﬀerences and
underlie the autism phenotype. The absence of expression
of the predicted human creatine transporter paralogous gene
(SLC6A10)inaccessibletissuesmakesitcurrentlyimpossible
to investigate this further.
Conﬁrmation of whether a defective chromosome 16
paralogous SLC6A8 gene causes autism should come from
observing rearrangements of this gene in other autistic
patients. Coding and intronic regions have to be screened to
establish if mutations in the SLC6A8 paralogous gene are the
cause of autism in a fraction of nontranslocation subjects.
Validation of the candidate gene identiﬁed here will rely on
association studies in patients and families with autism.
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